Back to Ingredient Dictionary
Common Name(s): P-butylresorcinol,rucinol
CAS Number: 18979-61-8
DESCRIPTION
What It Does: Provides exceptional brightening through the most potent tyrosinase inhibition of any commonly used cosmetic brightening agent.
Why It's Used: The most potent tyrosinase inhibitor available in cosmetics โ exceptional for refractory hyperpigmentation and melasma where standard brighteners provide insufficient efficacy.
How It Works: Resorcinol backbone competitively inhibits both tyrosine hydroxylase (reaction 1) and dopa oxidase (reaction 2) activities of tyrosinase. n-butyl chain provides superior membrane affinity for enhanced delivery to melanosomes.
Typically Found In: High-potency brightening serums,melasma treatments,stubborn hyperpigmentation products
TECHNICAL DETAILS
Primary Category: Active ingredient โ resorcinol tyrosinase inhibitor
Secondary Functions: Dual tyrosinase reaction inhibition,potent brightening
Application Areas:
Facial Skincare
Body Care
Hair Care
Beard Care
Color Cosmetics (Makeup)
Dietary/Oral Supplements
Typical Concentration Range: 0.1%โ1%
SOURCING & ETHICS
Vegan Status: Yes โ synthetic
Halal Status: Yes
Source Notes: Synthetic or plant-derived.
SKIN COMPATIBILITY
Irritancy Rating: 2/5 โ low to moderate
Comedogenicity Rating: 0/5 โ non-comedogenic
Sensitivity Concerns: Use with spf; introduce gradually. photosensitizing.
Safe for Sensitive Skin: Yes
SAFETY & COMPATIBILITY
Safety Profile: Excellent safety profile. use with spf for maximum efficacy. ewg score: 1.
Works Well With: Niacinamide,vitamin c,alpha-arbutin,tranexamic acid,spf
Avoid Combining With: No significant incompatibilities
SCIENTIFIC NOTE
4-butylresorcinol's inhibition of both tyrosinase catalytic reactions (tyrosineโdopa and dopaโdopaquinoneoxidase) is unique among common brighteners. most tyrosinase inhibitors only block the first reaction (tyrosineโdopa). blocking both steps provides more complete melanin biosynthesis inhibition.
Last Verified: Cosing database,choi et al. 4-butylresorcinol study,sccs opinion on butylresorcinol
Primary Sources: 2026-03-12